Cargando…
Long COVID: The Nature of Thrombotic Sequelae Determines the Necessity of Early Anticoagulation
Many discharged COVID-19 patients affected by sequelae experience reduced quality of life leading to an increased burden on the healthcare system, their families and society at large. Possible pathophysiological mechanisms of long COVID include: persistent viral replication, chronic hypoxia and infl...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9016198/ https://www.ncbi.nlm.nih.gov/pubmed/35449732 http://dx.doi.org/10.3389/fcimb.2022.861703 |
_version_ | 1784688478115594240 |
---|---|
author | Wang, Chengyue Yu, Chengyuan Jing, Haijiao Wu, Xiaoming Novakovic, Valerie A. Xie, Rujuan Shi, Jialan |
author_facet | Wang, Chengyue Yu, Chengyuan Jing, Haijiao Wu, Xiaoming Novakovic, Valerie A. Xie, Rujuan Shi, Jialan |
author_sort | Wang, Chengyue |
collection | PubMed |
description | Many discharged COVID-19 patients affected by sequelae experience reduced quality of life leading to an increased burden on the healthcare system, their families and society at large. Possible pathophysiological mechanisms of long COVID include: persistent viral replication, chronic hypoxia and inflammation. Ongoing vascular endothelial damage promotes platelet adhesion and coagulation, resulting in the impairment of various organ functions. Meanwhile, thrombosis will further aggravate vasculitis contributing to further deterioration. Thus, long COVID is essentially a thrombotic sequela. Unfortunately, there is currently no effective treatment for long COVID. This article summarizes the evidence for coagulation abnormalities in long COVID, with a focus on the pathophysiological mechanisms of thrombosis. Extracellular vesicles (EVs) released by various types of cells can carry SARS-CoV-2 through the circulation and attack distant tissues and organs. Furthermore, EVs express tissue factor and phosphatidylserine (PS) which aggravate thrombosis. Given the persistence of the virus, chronic inflammation and endothelial damage are inevitable. Pulmonary structural changes such as hypertension, embolism and fibrosis are common in long COVID. The resulting impaired lung function and chronic hypoxia again aggravates vascular inflammation and coagulation abnormalities. In this article, we also summarize recent research on antithrombotic therapy in COVID-19. There is increasing evidence that early anticoagulation can be effective in improving outcomes. In fact, persistent systemic vascular inflammation and dysfunction caused by thrombosis are key factors driving various complications of long COVID. Early prophylactic anticoagulation can prevent the release of or remove procoagulant substances, thereby protecting the vascular endothelium from damage, reducing thrombotic sequelae, and improving quality of life for long-COVID patients. |
format | Online Article Text |
id | pubmed-9016198 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90161982022-04-20 Long COVID: The Nature of Thrombotic Sequelae Determines the Necessity of Early Anticoagulation Wang, Chengyue Yu, Chengyuan Jing, Haijiao Wu, Xiaoming Novakovic, Valerie A. Xie, Rujuan Shi, Jialan Front Cell Infect Microbiol Cellular and Infection Microbiology Many discharged COVID-19 patients affected by sequelae experience reduced quality of life leading to an increased burden on the healthcare system, their families and society at large. Possible pathophysiological mechanisms of long COVID include: persistent viral replication, chronic hypoxia and inflammation. Ongoing vascular endothelial damage promotes platelet adhesion and coagulation, resulting in the impairment of various organ functions. Meanwhile, thrombosis will further aggravate vasculitis contributing to further deterioration. Thus, long COVID is essentially a thrombotic sequela. Unfortunately, there is currently no effective treatment for long COVID. This article summarizes the evidence for coagulation abnormalities in long COVID, with a focus on the pathophysiological mechanisms of thrombosis. Extracellular vesicles (EVs) released by various types of cells can carry SARS-CoV-2 through the circulation and attack distant tissues and organs. Furthermore, EVs express tissue factor and phosphatidylserine (PS) which aggravate thrombosis. Given the persistence of the virus, chronic inflammation and endothelial damage are inevitable. Pulmonary structural changes such as hypertension, embolism and fibrosis are common in long COVID. The resulting impaired lung function and chronic hypoxia again aggravates vascular inflammation and coagulation abnormalities. In this article, we also summarize recent research on antithrombotic therapy in COVID-19. There is increasing evidence that early anticoagulation can be effective in improving outcomes. In fact, persistent systemic vascular inflammation and dysfunction caused by thrombosis are key factors driving various complications of long COVID. Early prophylactic anticoagulation can prevent the release of or remove procoagulant substances, thereby protecting the vascular endothelium from damage, reducing thrombotic sequelae, and improving quality of life for long-COVID patients. Frontiers Media S.A. 2022-04-05 /pmc/articles/PMC9016198/ /pubmed/35449732 http://dx.doi.org/10.3389/fcimb.2022.861703 Text en Copyright © 2022 Wang, Yu, Jing, Wu, Novakovic, Xie and Shi https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cellular and Infection Microbiology Wang, Chengyue Yu, Chengyuan Jing, Haijiao Wu, Xiaoming Novakovic, Valerie A. Xie, Rujuan Shi, Jialan Long COVID: The Nature of Thrombotic Sequelae Determines the Necessity of Early Anticoagulation |
title | Long COVID: The Nature of Thrombotic Sequelae Determines the Necessity of Early Anticoagulation |
title_full | Long COVID: The Nature of Thrombotic Sequelae Determines the Necessity of Early Anticoagulation |
title_fullStr | Long COVID: The Nature of Thrombotic Sequelae Determines the Necessity of Early Anticoagulation |
title_full_unstemmed | Long COVID: The Nature of Thrombotic Sequelae Determines the Necessity of Early Anticoagulation |
title_short | Long COVID: The Nature of Thrombotic Sequelae Determines the Necessity of Early Anticoagulation |
title_sort | long covid: the nature of thrombotic sequelae determines the necessity of early anticoagulation |
topic | Cellular and Infection Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9016198/ https://www.ncbi.nlm.nih.gov/pubmed/35449732 http://dx.doi.org/10.3389/fcimb.2022.861703 |
work_keys_str_mv | AT wangchengyue longcovidthenatureofthromboticsequelaedeterminesthenecessityofearlyanticoagulation AT yuchengyuan longcovidthenatureofthromboticsequelaedeterminesthenecessityofearlyanticoagulation AT jinghaijiao longcovidthenatureofthromboticsequelaedeterminesthenecessityofearlyanticoagulation AT wuxiaoming longcovidthenatureofthromboticsequelaedeterminesthenecessityofearlyanticoagulation AT novakovicvaleriea longcovidthenatureofthromboticsequelaedeterminesthenecessityofearlyanticoagulation AT xierujuan longcovidthenatureofthromboticsequelaedeterminesthenecessityofearlyanticoagulation AT shijialan longcovidthenatureofthromboticsequelaedeterminesthenecessityofearlyanticoagulation |